RYR · Monascus purpureus · red rice yeast · hong qu
600 mg · vegan · gluten-free · 120 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Red yeast rice is a traditional Chinese food and medicine made by fermenting rice with Monascus purpureus yeast. It contains monacolin K, which is chemically identical to the active ingredient in lovastatin, along with other monacolins, sterols, and isoflavones.
Monacolin K inhibits HMG-CoA reductase, the same enzyme targeted by statin medications, reducing cholesterol synthesis in the liver. The fermentation process also produces other compounds that may contribute to lipid-lowering effects.
Adults with elevated cholesterol seeking natural alternatives, individuals intolerant to prescription statins, those interested in traditional lipid support.
People taking prescription statins (risk of additive toxicity), those with liver disease, pregnant or breastfeeding women, children, individuals with kidney disease.
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Evening aligns with peak cholesterol synthesis; split dose for higher amounts
✓ Food reduces GI discomfort and improves tolerance
Monacolin K inhibits HMG-CoA reductase, the same enzyme targeted by statin medications, reducing cholesterol synthesis in the liver.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Dyslipidaemia cohort (n≈75)
Target LDL <100 mg/dL for cardiovascular risk reduction.
see study
→ RYR 1,800 mg/day reduced LDL by 43 mg/dL vs placebo; no myalgia difference (N=62, 24 weeks)
see study
→ Xuezhikang reduced coronary events by 45%, all-cause mortality by 33% (N=4,870, 4.5 years)
see study
→ Meta-analysis: RYR reduced LDL by 1.02 mmol/L, total cholesterol by 0.96 mmol/L (N=13 trials)
B · Strong lipid-lowering data; cardiovascular outcome data from CCSPS; citrinin contamination risk requires product selection
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 25532863 (Liu 2006, LDL meta-analysis ↓15-25%), PMID 19099555 (Heber 2009, RCT n=62 statin intolerant), PMID 29628337 (Pirro 2016, systematic review 12 trials).
How to use Red Yeast Rice specifically for high cholesterol — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of Red Yeast Rice — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about Red Yeast Rice — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on Red Yeast Rice — context the structured blocks above don't capture.
Red yeast rice occupies a unique regulatory gray zone: it is a dietary supplement that contains a compound chemically identical to a prescription drug. Monacolin K, produced by Monascus purpureus fermentation, is lovastatin in all but name. This identity creates both therapeutic potential and significant safety concerns that honest framing must address.
The lipid-lowering evidence is robust. Becker and colleagues (2009, Annals of Internal Medicine, PMID 19153407) randomized 62 statin-intolerant patients to red yeast rice 1,800 mg daily or placebo for 24 weeks. The RYR group achieved a 43 mg/dL reduction in LDL cholesterol—comparable to low-dose statin effects—without the myalgia that had forced these patients off prescription therapy. This is not a marginal effect; it represents genuine pharmacological activity. The China Coronary Secondary Prevention Study (CCSPS, PMID 18458257) provided even more compelling data: 4,870 patients with prior myocardial infarction took Xuezhikang (a refined RYR extract) for 4.5 years, achieving 45% reduction in coronary events and 33% reduction in all-cause mortality. These are hard cardiovascular endpoints, not surrogate markers.
The citrinin contamination issue is serious and non-negotiable. Citrinin is a mycotoxin produced by some Monascus strains that is nephrotoxic in animal models. The FDA has warned consumers about citrinin-contaminated RYR products, and independent testing has found variable levels across brands. Reputable manufacturers test and certify citrinin-free status, but this is not universally required. The honest framing: RYR works because it contains a statin, and carries statin-like risks (muscle toxicity, liver enzyme elevation) plus the unique risk of mycotoxin contamination. It is not a “natural” alternative free of pharmaceutical concerns.
Regulatory status varies globally. In the United States, the FDA has attempted to regulate RYR products containing substantial monacolin K as unapproved drugs, but enforcement has been inconsistent. The European Union requires citrinin limits. Consumers should select products from manufacturers that provide third-party testing for both monacolin K content and citrinin absence. The dose-response relationship is established: 1,200–2,400 mg of RYR providing approximately 10–20 mg monacolin K produces meaningful LDL reduction. Lower doses or products with degraded monacolin K content may be ineffective.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
